Hengrui Pharma surges 11% as Q3 profit beats estimates

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hengrui Pharma (1276.HK) surged more than 11% in Hong Kong trading to HK$49.78.

The company reported third-quarter revenue of 8.953 billion yuan, up 20.55% year-over-year, while net income attributable to shareholders rose 88.92% to 2.458 billion yuan, topping market expectations. Innovative drug sales reached 13.871 billion yuan in the first nine months, up 17.05% from a year earlier and accounting for 64.59% of total pharmaceutical revenue; licensing income climbed 31.12% to 2.781 billion yuan, driving overall performance back to double-digit growth.

Separately, Hengrui received approval for a new indication of its Class 1 innovative drug remimazolam tosilate for injection, intended for sedation during mechanical ventilation in intensive care units, with cumulative R&D investment of approximately 223 million yuan. Additionally, three drug candidates — SHR-2005 injection, SHR-1501 for injection and adebrelimab injection — received clinical trial approval from China’s National Medical Products Administration.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.